预防性输卵管卵巢切除术在遗传性卵巢癌中的应用

冯征; 温灏

doi:10.19401/j.cnki.1007-3639.2022.11.002

您当前的位置：

首页 >

文章列表页 >

预防性输卵管卵巢切除术在遗传性卵巢癌中的应用

专家述评 | 更新时间：2025-12-31

- 预防性输卵管卵巢切除术在遗传性卵巢癌中的应用
- Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer
- 中国癌症杂志 2022年32卷第11期页码：1044-1048
- 作者机构：
  
  1. 复旦大学附属肿瘤医院肿瘤妇科，复旦大学上海医学院肿瘤学系，上海 200032
  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
- 作者简介：
  
  [ "冯征（ORCID: 0000-0003-2561-3869），博士，主治医师。" ]
  [ "温灏，医学博士，副主任医师，复旦大学附属肿瘤医院肿瘤妇科行政副主任。中国抗癌协会妇科肿瘤专业委员会委员、秘书长，中国抗癌协会妇科肿瘤科普教育基地专业委员会委员、秘书长，中国抗癌协会肿瘤标志专业委员会妇科肿瘤标志物专家学组副组长，上海市抗癌协会青年理事会理事，上海市抗癌协会肿瘤药物临床研究专业委员会委员，上海市医学会妇科肿瘤学分会卵巢癌学组副组长。Gynecology and Pelvic Medicine编委，《现代妇产科进展》《肿瘤药学》编委。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.11.002
  中图分类号： R737.31
- 收稿：2022-10-23，
  
  修回：2022-11-15，
  
  纸质出版：2022-11-30
- 稿件说明：
移动端阅览
冯征, 温灏. 预防性输卵管卵巢切除术在遗传性卵巢癌中的应用[J]. 中国癌症杂志, 2022,32(11):1044-1048.

Zheng FENG, Hao WEN. Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer[J]. China Oncology, 2022, 32(11): 1044-1048.
冯征, 温灏. 预防性输卵管卵巢切除术在遗传性卵巢癌中的应用[J]. 中国癌症杂志, 2022,32(11):1044-1048. DOI： 10.19401/j.cnki.1007-3639.2022.11.002.

Zheng FENG, Hao WEN. Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer[J]. China Oncology, 2022, 32(11): 1044-1048. DOI： 10.19401/j.cnki.1007-3639.2022.11.002.

摘要

卵巢癌是危害女性生命健康的常见疾病。目前尚无有效的卵巢癌筛查及早期诊断方法，多数卵巢癌发现时已为晚期，总体疗效并不理想。流行病学研究显示，携带相关基因突变的女性罹患卵巢癌的概率显著提高。因此，对其进行预防干预十分重要。预防性输卵管卵巢切除术是目前降低高风险女性卵巢癌发病率的最有效手段。手术和病理取材的规范性是预防性手术发挥作用的有力保障。本文旨在探讨预防性手术在遗传性卵巢癌中应用的现状及争议，以期使预防性手术的开展更加规范化、个体化。

Abstract

Ovarian cancer is one of the most common and lethal diseases among females. Due to the difficulty of surveillance and early detection

most ovarian cancers were diagnosed at advanced stage with poor outcomes. Epidemiological studies indicate that women with deleterious gene mutations have higher susceptibility of ovarian cancer. Thus

it is pivotal to prevent its occurrence. Risk-reducing salpingo-oophorectomy is the most effective method to prevent women at high risk from ovarian cancer. It depends on the standardization of the surgical and pathological procedure. In this article

we aimed to elucidate the current status and controversy of this risk-reducing surgery.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660

CHEN W Q , ZHENG R S , BAADE P D , et al. Cancer statistics in China, 2015 [J ] . CA Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 . DOI: 10.3322/caac.21338 http://doi.org/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338 http://doi.wiley.com/10.3322/caac.21338

BEREK J S , KEHOE S T , KUMAR L , et al. Cancer of the ovary, fallopian tube, and peritoneum [J ] . Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet , 2018 , 143 ( Suppl 2 ): 59 - 78 .

SOWTER H M , ASHWORTH A . BRCA 1 and BRCA 2 as ovarian cancer susceptibility genes [J ] . Carcinogenesis , 2005 , 26 ( 10 ): 1651 - 1656 . DOI: 10.1093/carcin/bgi136 http://doi.org/10.1093/carcin/bgi136 http://academic.oup.com/carcin/article/26/10/1651/2390720/BRCA1-and-BRCA2-as-ovarian-cancer-susceptibility http://academic.oup.com/carcin/article/26/10/1651/2390720/BRCA1-and-BRCA2-as-ovarian-cancer-susceptibility

MAVADDAT N , PEOCK S , FROST D , et al. Cancer risks for BRCA 1 and BRCA 2 mutation carriers: results from prospective analysis of EMBRACE [J ] . J Natl Cancer Inst , 2013 , 105 ( 11 ): 812 - 822 . DOI: 10.1093/jnci/djt095 http://doi.org/10.1093/jnci/djt095 https://academic.oup.com/jnci/article/105/11/812/1004115 https://academic.oup.com/jnci/article/105/11/812/1004115

HALL M J , OBEID E I , SCHWARTZ S C , et al. Genetic testing for hereditary cancer predisposition: BRCA 1/2, Lynch syndrome, and beyond [J ] . Gynecol Oncol , 2016 , 140 ( 3 ): 565 - 574 . DOI: 10.1016/j.ygyno.2016.01.019 http://doi.org/10.1016/j.ygyno.2016.01.019 https://linkinghub.elsevier.com/retrieve/pii/S0090825816300166 https://linkinghub.elsevier.com/retrieve/pii/S0090825816300166

PENNINGTON K P , WALSH T , HARRELL M I , et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas [J ] . Clin Cancer Res , 2014 , 20 ( 3 ): 764 - 775 . DOI: 10.1158/1078-0432.CCR-13-2287 http://doi.org/10.1158/1078-0432.CCR-13-2287

DALY M B , PAL T , BERRY M P , et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology [J ] . J Natl Compr Canc Netw , 2021 , 19 ( 1 ): 77 - 102 . DOI: 10.6004/jnccn.2021.0001 http://doi.org/10.6004/jnccn.2021.0001 https://jnccn.org/view/journals/jnccn/19/1/article-p77.xml https://jnccn.org/view/journals/jnccn/19/1/article-p77.xml

KURMAN R J , SHIH I M . The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory [J ] . Am J Surg Pathol , 2010 , 34 ( 3 ): 433 - 443 . DOI: 10.1097/PAS.0b013e3181cf3d79 http://doi.org/10.1097/PAS.0b013e3181cf3d79

ACOG committee opinion no. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention [J ] . Obstet Gynecol , 2019 , 133 ( 4 ): e279 -e284. DOI: 10.1097/AOG.0000000000003164 http://doi.org/10.1097/AOG.0000000000003164 https://journals.lww.com/00006250-201904000-00059 https://journals.lww.com/00006250-201904000-00059

DOMINGUEZ-VALENTIN M , SAMPSON J R , SEPPÄLÄ T T , et al. Cancer risks by gene, age, and gender in 6 350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database [J ] . Genet Med , 2020 , 22 ( 1 ): 15 - 25 .

SONG H L , DICKS E M , TYRER J , et al. Population-based targeted sequencing of 54 candidate genes identifies PALB 2 as a susceptibility gene for high-grade serous ovarian cancer [J ] . J Med Genet , 2021 , 58 ( 5 ): 305 - 313 . DOI: 10.1136/jmedgenet-2019-106739 http://doi.org/10.1136/jmedgenet-2019-106739 https://jmg.bmj.com/lookup/doi/10.1136/jmedgenet-2019-106739 https://jmg.bmj.com/lookup/doi/10.1136/jmedgenet-2019-106739

WU N Y Y , FANG C , HUANG H S , et al. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions [J ] . Mod Pathol , 2020 , 33 ( 1 ): 29 - 37 . DOI: 10.1038/s41379-019-0370-1 http://doi.org/10.1038/s41379-019-0370-1 https://doi.org/10.1038/s41379-019-0370-1 https://doi.org/10.1038/s41379-019-0370-1

SHU C A , PIKE M C , JOTWANI A R , et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations [J ] . JAMA Oncol , 2016 , 2 ( 11 ): 1434 - 1440 . DOI: 10.1001/jamaoncol.2016.1820 http://doi.org/10.1001/jamaoncol.2016.1820 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1820 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.1820

STEENBEEK M P , HARMSEN M G , HOOGERBRUGGE N , et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA 1/2 pathogenic variant carriers: a nonrandomized controlled trial [J ] . JAMA Oncol , 2021 , 7 ( 8 ): 1203 - 1212 . DOI: 10.1001/jamaoncol.2021.1590 http://doi.org/10.1001/jamaoncol.2021.1590 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780476 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780476

MEDEIROS F , MUTO M G , LEE Y , et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome [J ] . Am J Surg Pathol , 2006 , 30 ( 2 ): 230 - 236 .

FOLKINS A K , JARBOE E A , SALEEMUDDIN A , et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations [J ] . Gynecol Oncol , 2008 , 109 ( 2 ): 168 - 173 . DOI: 10.1016/j.ygyno.2008.01.012 http://doi.org/10.1016/j.ygyno.2008.01.012 https://linkinghub.elsevier.com/retrieve/pii/S0090825808000073 https://linkinghub.elsevier.com/retrieve/pii/S0090825808000073

VISVANATHAN K , SHAW P , MAY B J , et al. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study [J ] . Cancer Prev Res (Phila) , 2018 , 11 ( 11 ): 697 - 706 . DOI: 10.1158/1940-6207.CAPR-18-0009 http://doi.org/10.1158/1940-6207.CAPR-18-0009 https://aacrjournals.org/cancerpreventionresearch/article/11/11/697/46908/Fallopian-Tube-Lesions-in-Women-at-High-Risk-for https://aacrjournals.org/cancerpreventionresearch/article/11/11/697/46908/Fallopian-Tube-Lesions-in-Women-at-High-Risk-for

AKAHANE T , MASUDA K , HIRASAWA A , et al. TP 53 variants in p53 signatures and the clonality of STICs in RRSO samples [J ] . J Gynecol Oncol , 2022 , 33 ( 4 ): e50 . DOI: 10.3802/jgo.2022.33.e50 http://doi.org/10.3802/jgo.2022.33.e50

LÕHMUSSAAR K , KOPPER O , KORVING J , et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids [J ] . Nat Commun , 2020 , 11 ( 1 ): 2660 . DOI: 10.1038/s41467-020-16432-0 http://doi.org/10.1038/s41467-020-16432-0

VAN DER HOEVEN N M A , VAN WIJK K , BONFRER S E , et al. Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review [J ] . Clin Oncol (R Coll Radiol) , 2018 , 30 ( 8 ): 463 - 471 . DOI: S0936-6555(18)30209-7 http://doi.org/S0936-6555(18)30209-7

PATRONO M G , INIESTA M D , MALPICA A , et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review [J ] . Gynecol Oncol , 2015 , 139 ( 3 ): 568 - 572 . DOI: 10.1016/j.ygyno.2015.09.018 http://doi.org/10.1016/j.ygyno.2015.09.018

CHENG A S , LI L , WU M , et al. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis [J ] . Eur J Surg Oncol , 2020 , 46 ( 1 ): 139 - 147 . DOI: 10.1016/j.ejso.2019.09.002 http://doi.org/10.1016/j.ejso.2019.09.002 https://linkinghub.elsevier.com/retrieve/pii/S0748798319306626 https://linkinghub.elsevier.com/retrieve/pii/S0748798319306626

RUSH S K , SWISHER E M , GARCIA R L , et al. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience [J ] . Gynecol Oncol , 2020 , 157 ( 2 ): 514 - 520 . DOI: S0090-8258(20)30101-3 http://doi.org/S0090-8258(20)30101-3

SHERMAN M E , PIEDMONTE M , MAI P L , et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199 [J ] . J Clin Oncol , 2014 , 32 ( 29 ): 3275 - 3283 . DOI: 10.1200/JCO.2013.54.1987 http://doi.org/10.1200/JCO.2013.54.1987

DOWDY S C , STEFANEK M , HARTMANN L C . Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy [J ] . Am J Obstet Gynecol , 2004 , 191 ( 4 ): 1113 - 1123 .

STEENBEEK M P , VAN BOMMEL M H D , BULTEN J , et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis [J ] . J Clin Oncol , 2022 , 40 ( 17 ): 1879 - 1891 . DOI: 10.1200/JCO.21.02016 http://doi.org/10.1200/JCO.21.02016 https://ascopubs.org/doi/10.1200/JCO.21.02016 https://ascopubs.org/doi/10.1200/JCO.21.02016

VAN WINDEN L J , VERMEULEN R F M , VAN DEN NOORT V , et al. Changes in sex steroids and relation with menopausal complaints in women undergoing risk-reducing salpingo-oophorectomy [J ] . J Endocr Soc , 2022 , 6 ( 6 ): bvac069 . DOI: 10.1210/jendso/bvac069 http://doi.org/10.1210/jendso/bvac069 https://academic.oup.com/jes/article/doi/10.1210/jendso/bvac069/6573970 https://academic.oup.com/jes/article/doi/10.1210/jendso/bvac069/6573970

MOSS K M , MISHRA G D , KREJANY E O , et al. What happens after menopause? (WHAM): a prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy [J ] . Gynecol Oncol , 2022 , 167 ( 1 ): 58 - 64 . DOI: 10.1016/j.ygyno.2022.07.029 http://doi.org/10.1016/j.ygyno.2022.07.029 https://linkinghub.elsevier.com/retrieve/pii/S0090825822005133 https://linkinghub.elsevier.com/retrieve/pii/S0090825822005133

MAI P L , MILLER A , BLACK A , et al. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study [J ] . Am J Obstet Gynecol , 2022 , 227 ( 1 ): 61. e1 - 61 .61.e18.

浏览量

2686

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

外泌体中ISG15在卵巢癌铂类药物耐药中的作用及初步机制探讨

2023年度妇科恶性肿瘤治疗进展及展望

卵巢黏液性癌的诊治进展

2023年ESMO妇科肿瘤治疗最新进展及展望

2022年度妇科肿瘤诊治进展